Theon Pharma Launches New Bi-Layered Respiratory Tablet

Theon Pharma Launches New Bi-Layered Respiratory Tablet

Theon Pharmaceuticals recently introduced a novel Acebrophylline and Erdosteine combination in the Indian market. This film-coated bi-layered tablet represents a significant breakthrough for treating chronic bronchitis in patients with COPD. Theon Pharma is the first CDMO in India to receive a DCGI license for this formulation. Consequently, the product addresses an urgent unmet need in long-term respiratory management. Furthermore, this innovation highlights the company’s commitment to delivering clinically superior products, a goal often emphasized in advanced respiratory medicine.

Pharmacological Synergy of the Acebrophylline and Erdosteine combination

This innovative combination brings together two well-established molecules with complementary mechanisms of action. Acebrophylline acts as a bronchodilator and mucoregulator with anti-inflammatory properties. Meanwhile, Erdosteine functions as a potent mucolytic with additional antioxidant and anti-inflammatory benefits. Together, they effectively enhance mucus clearance and reduce airway inflammation. Therefore, the combination effectively improves overall pulmonary function for patients.

From a pharmacological perspective, Acebrophylline stimulates surfactant production and reduces bronchial hyper-responsiveness. It also improves ventilatory capacity significantly. On the other hand, Erdosteine reduces mucus viscosity by breaking disulfide bonds within the mucus. It additionally suppresses pro-inflammatory cytokines while providing antioxidant protection against oxidative stress. For clinicians looking to deepen their expertise, pursuing a Postgraduate Diploma In Respiratory Medicine can provide valuable insights into managing such complex airway conditions.

Advanced Bi-Layered Technology and Patient Outcomes

One of the most significant advancements in this product is its patented bi-layered tablet design. This specific technology allows for optimized release kinetics of both active molecules. As a result, the formulation ensures better therapeutic outcomes and improved patient compliance. Moreover, the bi-layered design enhances the stability of the combination. Because of these technical advantages, it stands as a superior alternative to traditional treatments.

Clinically, this combination offers several advantages over widely used Acebrophylline and Acetylcysteine products. It provides enhanced mucociliary clearance and reduces the frequency of COPD exacerbations. Furthermore, patients experience better lung function and a higher quality of life. Because it has better tolerability, it is particularly suitable for long-term therapy. Ultimately, this product positions Theon Pharma as a leader in India’s competitive respiratory segment. Professionals involved in chronic disease management may also benefit from a Certification Course In Asthma Diagnosis And Management to further refine their approach to obstructive airway diseases.

Frequently Asked Questions

Q1: What are the primary benefits of the Acebrophylline and Erdosteine combination?

This combination enhances mucus clearance, reduces airway inflammation, and improves overall pulmonary function in COPD patients.

Q2: How does the bi-layered technology help patients?

The patented bi-layered design optimizes the release of each drug, which leads to better therapeutic effects, improved stability, and higher patient compliance.

Q3: Is this combination suitable for long-term use?

Yes, it is specifically designed for long-term management of chronic bronchitis and COPD, offering better tolerability than many existing combinations.

References

1. Theon Pharma Launches Bi-Layered Acebrophylline–Erdosteine Platform forRespiratory Care – ETHealthworld
2. Mungantiwar, A., Shrivastava, P., & Wattamwar, T. (2025). A Randomized, Open-Label, Phase 3 Clinical Trial of FDC Erdosteine 300 mg and Acebrophylline 100 mg Tablet. International Journal of Science and Research (IJSR).
3. Cazzola, M., et al. (2017). Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease. BMC Pulmonary Medicine.

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.